RESUMO
OBJECTIVE: Inflammation plays a crucial part in osteoarthritis (OA) development. This work aimed to explore loganin's role and molecular mechanism in inflammation and clarify its anti-inflammatory effects in OA treatment. METHODS: Chondrocytes were stimulated using interleukin (IL)-1ß and loganin at two concentrations (1 µM and 10 µM). Nitric oxide (NO) and prostaglandin E2 (PGE2) expression was assessed. Real-time polymerase chain reaction was used to evaluate inducible NO synthase (iNOS), cyclooxygenase (COX)-2, IL-6, and tumor necrosis factor (TNF)-α mRNA levels. Western blot was used to investigate TLR4, MyD88, p-p65, and IκB-α expression. p65 nuclear translocation, synovial inflammatory response, and cartilage degeneration were also assessed. RESULTS: Loganin significantly reduced IL-1ß-mediated PGE2, NO, iNOS, and COX-2 expression compared with that of the IL-1ß stimulation group. The TLR4/MyD88/NF-κB pathway was suppressed by loganin, which decreased inflammatory cytokine (TNF-α and IL-6) levels compared with those of the IL-1ß stimulation group. Loganin inhibited IL-1ß-mediated NF-κB p65 nuclear translocation compared with that of the IL-1ß stimulation group. Loganin partially suppressed cartilage degeneration and the synovial inflammatory response in vivo. CONCLUSION: This work demonstrated that loganin inhibited IL-1ß-mediated inflammation in rat chondrocytes through TLR4/MyD88/NF-κB pathway regulation, thereby reducing rat cartilage degeneration and the synovial inflammatory response.
